Field evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia.
MetadataShow full item record
JournalJournal of Viral Hepatitis
AbstractGeneXpert® (Cepheid) is the only WHO prequalified platform for hepatitis C virus (HCV) nucleic acid amplification testing that is suitable for point-of-care use in resource-limited contexts. However, its application is constrained by the lack of evidence on genotype 6 (GT6) HCV. We evaluated its field performance among a patient population in Cambodia predominantly infected with GT6. Between August and September 2017, we tested plasma samples obtained from consenting patients at Médecins Sans Frontières' HCV clinic at Preah Kossamak Hospital for HCV viral load (VL) using GeneXpert® and compared its results to those obtained using COBAS® AmpliPrep/Cobas® TaqMan® HCV Quantitative Test, v2.0 (Roche) at the Institut Pasteur du Cambodge. Among 769 patients, 77% of the seropositive patients (n = 454/590) had detectable and quantifiable VL using Roche and 43% (n = 195/454) were GT6. The sensitivity and specificity of GeneXpert® against Roche were 100% (95% CI 99.2, 100.0) and 98.5% (95% CI 94.8, 99.8). The mean VL difference was -0.01 (95% CI -0.05, 0.02) log10 IU/mL for 454 samples quantifiable on Roche and -0.07 (95% CI -0.12, -0.02) log10 IU/mL for GT6 (n = 195). The limit of agreement (LOA) was -0.76 to 0.73 log10 IU/mL for all GTs and -0.76 to 0.62 log10 IU/mL for GT6. Twenty-nine GeneXpert® results were outside the LOA. Frequency of error and the median turnaround time (TAT) for GeneXpert® were 1% and 0 days (4 days using Roche). We demonstrated that the GeneXpert® HCV assay has good sensitivity, specificity, quantitative agreement, and TAT in a real-world, resource-limited clinical setting among GT6 HCV patients.
- Rapid point-of-care HCV RNA quantification in capillary whole blood for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection.
- Authors: Bregenzer A, Warmann N, Ottiger C, Fux CA
- Issue date: 2019 Oct 7
- Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test.
- Authors: Pierce VM, Eversley JS, Tran TK, Rosenberg ES
- Issue date: 2017 Jun 27
- Analytical characteristics and comparative evaluation of Aptima HCV quant Dx assay with the Abbott RealTime HCV assay and Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative test v2.0.
- Authors: Worlock A, Blair D, Hunsicker M, Le-Nguyen T, Motta C, Nguyen C, Papachristou E, Pham J, Williams A, Vi M, Vinluan B, Hatzakis A
- Issue date: 2017 Apr 4
- Hepatitis Screening and Treatment Campaign in Malaysia-Validation of Low-cost Point of Care Screening Tests and Nucleic Acid Tests for Hepatitis B and C.
- Authors: Radzi Ah M, S Tan S, Mohamed R, Jaya F, K S, C Aun A, A Kutty G, S Wong H, Abdullah R, R Seman M, Al Mahtab M, Morad Z, Lim TO
- Issue date: 2018 Jul-Dec
- Verification of the Roche cobas<sup>®</sup> 6800 PCR 200 µl and 500 µl protocols for the quantification of HIV-1 RNA, HBV DNA and HCV RNA and evaluation with COBAS<sup>®</sup> Ampliprep/COBAS<sup>®</sup> TaqMan<sup>®</sup> assays.
- Authors: Tan NK, Carrington D, Pope CF
- Issue date: 2018 Dec